Fate of 23andMe genetic data still not settled amid bankruptcy fight
23andMe is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, casting doubt on its deal with Regeneron Pharmaceuticals.
View original article
Contributor: Daniel Gilbert, Elizabeth Dwoskin
